PSMA Ligand Complexes for Tumor Targeting and Reduced Off-Target Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and therapeutic agents for prostate cancer, particularly those targeting PSMA, face challenges such as unspecific 'off-target' interactions, accumulation in normal tissues, and poor pharmacokinetic properties, leading to inadequate tumor targeting and potential tissue damage.
Innovation Solution
Development of novel PSMA ligands with a chelating agent, an albumin-binding entity, and a PSMA-binding entity connected via suitable linkers and spacers, which form radiolabeled complexes for improved tumor targeting and reduced off-target effects by compartmentalization in the blood and extended blood clearance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If PSMA-targeting agents are used for imaging and therapy, then tumor targeting is improved, but off-target interactions and accumulation in normal tissues occur
Solution Approach 1:
The PSMA-targeting agent is divided into separate functional modules: a PSMA-binding entity (urea-based peptidomimetic), a chelating agent for radionuclide attachment, and optional additional moieties for imaging or therapy. This segmentation allows each component to be optimized independently while maintaining overall tumor specificity and reducing off-target effects through modular design.
Solution Approach 2:
The invention creates composite radiolabeled complexes by combining the PSMA-binding urea entity with chelating agents and radionuclides. These composite structures integrate multiple functions (targeting, imaging, therapy) into a single molecule, improving tumor uptake while controlling distribution patterns to minimize off-target accumulation through optimized pharmacokinetic properties.
2Reliability
If radiolabeled PSMA agents are administered, then diagnostic and therapeutic efficacy is achieved, but accumulation in excretory organs causes tissue damage
Solution Approach 1:
The invention optimizes pharmacokinetic parameters of the radiolabeled complexes including blood clearance rate, renal filtration, and urinary excretion patterns. By modifying molecular properties such as lipophilicity, molecular weight, and charge distribution, the agents achieve improved tumor uptake and altered biodistribution that reduces accumulation in kidneys and other excretory organs while maintaining diagnostic and therapeutic efficacy.
3Measurement precision
If high doses of radiolabeled agents are used to improve imaging quality, then imaging sensitivity increases, but side effects and tissue damage increase
Solution Approach 1:
The invention employs radiolabeled complexes where the radionuclide acts as a detectable copy or marker of the PSMA-binding molecule. This allows the imaging signal to be generated by the radionuclide copy without requiring high concentrations of the entire complex, thereby achieving high imaging sensitivity with lower administered doses and reduced side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel complexes exhibit enhanced tumor uptake and retention, reducing the required dose of radiolabels, minimizing side effects, and offering improved imaging and therapeutic efficacy with optimized pharmacokinetic profiles.
Implementation Method 1
radiolabeled complexes comprising a chelating agent, a PSMA-binding entity and an albumin-binding entity
Implementation Method 2
an albumin-binding entity connected via suitable linkers and spacers... extended blood clearance
Data Source
AI summary
The present invention provides novel compounds that are useful as radiopharmaceuticals, imaging agents and for treatment of cancer.